Skip to main content
 

Investors & Media

Corporate Profile
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi.
Recent News
September 14, 2016
WAVE Life Sciences to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
CAMBRIDGE, Mass--(BUSINESS WIRE)--Sep. 14, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:0... 
August 17, 2016
WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 17, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announced that it has appointed Keith Regnante as the company’s Chief Financial Officer. Mr. Regnante will provide strategic direction and bring substantial management experience to WAVE’s finance and operations functions. ... 
August 15, 2016
WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update
On track to file two INDs for lead programs in Huntington's disease in 2016 and IND for lead program in Duchenne muscular dystrophy in 2017 Current financial position supports continued pipeline progression, six clinical programs by 2018 and operations into 2019 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 15, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today reported fina... 

view all

Upcoming Events
There are currently no events scheduled.

view all